- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mo | Cybin's psychedelic depression drug reduces 12-month symptom severity | ||
| Mo | AHA 2024: Study shows gains with ablation before meds in treating v-tach after heart attack | ||
| Mo | AHA 2024: AI spots high blood pressure, diabetes in slow-motion video | ||
| Mo | CSL Behring shuts down California cell and gene therapy R&D site amid group pivot | ||
| Mo | Neurogene rethinks gene therapy trial after high dose leaves Rett patient in critical condition | ||
| Mo | Intellia's CRISPR and Alnylam's RNAi data drops present contrasting visions for cardiomyopathy care | ||
| Mo | Trogenix unveils odyssey to find one-time tumor drugs with 'unprecedented selectivity' | ||
| Fr | Philips obtains FDA clearance for radiotherapy scanner combing 4D and spectral CT in one scan | ||
| Fr | Boston Pharma hits phase 2 MASH goal, positioning monthly prospect to follow Akero, 89bio into pivotal trials | ||
| Fr | Biotechs behind J&J-bought Yellow Jersey partner on another immunology asset | ||
| Fr | Chutes & Ladders-Flagship-backed biotechs name new leaders | ||
| Fr | Halozyme offers $2B for Evotec to expand beyond delivery tech used by J&J and Roche | ||
| Fr | Omega halts sole clinical-stage program to prioritize Novo Nordisk collab and liver, obesity work | ||
| 14.11. | Muscular dystrophy gene therapy uses cells to stitch together mRNA strands in mice | ||
| 14.11. | Gilead lays off 72 workers in Seattle, plans to shutter R&D support site | ||
| 14.11. | BMS' CAR-T cracks down on lupus, achieving sustained responses in phase 1 | ||
| 14.11. | Sensei Bio lays off 46% of staff, closes research site to fund phase 2 cancer trial | ||
| 14.11. | FDA clears Omron blood pressure cuff with afib pulse wave detection | ||
| 14.11. | Merck pays $588M for bispecific to defend Keytruda's kingdom from emerging threat | ||
| 14.11. | Allogene abandons leukemia plans for CAR-T in wake of Breyanzi approval | ||
| 14.11. | Kronos shelves sole remaining clinical asset over neurological side effects | ||
| 14.11. | Gura's weekly amylin obesity asset well-tolerated, tied to weight loss in phase 1 trial | ||
| 13.11. | Adaptimmune gears up for another FDA submission after hitting goal in pivotal sarcoma study | ||
| 13.11. | It's all about the Journey: Entero inks reverse merger with ADC rival biotech | ||
| 13.11. | Syros flunks phase 3 blood cancer trial, triggering loan default and share-price plunge |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
